Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension

Thyroid

Volumn 20, Issue 10, 2010, Pages 1085-1093

  Rivera, Michael ^a   Ricarte Filho, Julio ^a   Tuttle, Robert Michael ^a   Ganly, Ian ^a   Shaha, Ashok ^a   Knauf, Jeffrey ^a   Fagin, James ^a   Ghossein, Ronald ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN KINASE B; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RET; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR NECROSIS;

CARCINOMA; CARCINOMA, PAPILLARY; ESOPHAGUS; HUMANS; NECROSIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TRACHEA; TREATMENT OUTCOME;

EID: 77957929765     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0174     Document Type: Article

References (21)

1. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J 1985 Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55:805-828.
2. Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP, Brennan MF, Shaha AR, Singh B 2001 Hurthle cell carcinoma. A critical histopathologic appraisal. J Clin Oncol 19:2616-2625.
3. Hiltzik D, Carlson DL, Tuttle MR, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA 2006 Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. Cancer 106:1286-1295.
4. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330-1335.
5. th edition). Springer, New York, pp 67-74.
6. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL Mclver B, Pacini F, Schlumberger M, Sherman SI, Stewart DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
7. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A 2006 Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30:780-786. (Pubitemid 43724106)
8. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004 World Health Organization Classification of Tumours. Pathology & Genetics Tumours of the Endocrine Organs. IARC Press, Lyon.
9. Lang W, Choritz H, Hundeshagen H 1986 Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 10:246-255.
10. Rosai J, Carcangiu ML, Delellis RA 1992 Tumors of the thyroid gland. In: Rosai J, Sobin LH (eds). Atlas of Tumor Pathology, volume 5. Armed Forces Institute of Pathology, New York, pp 161-182.
11. Ricarte-Filho JCM, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA and AKT1. Cancer Res 69:4885-4893.
12. Imkamp F, von Wasielewski R, Musholt TJ, Musholt PB 2007 Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts. J Surg Res 143:350-363.
13. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326.
14. Komorowski RA, Hanson GA 1998 Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol 19:689-696.
15. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle MR 2008 Histopathologic characterization of radioactive iodine refractory FDG-PET positive thyroid carcinoma. Cancer 113:48-56.
16. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features. Clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222.
17. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379.
18. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between B-RAFV600E mutation and clinic pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464.
19. Mesa C Jr., Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66:6521-6529.
20. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W 1992 Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23:1395-1401.
21. th annual meeting of the American Thyroid Association, New York, USA. Thyroid 17: S18.